Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring?
about
Different strategies for using topical corticosteroids for established eczemaTopical pimecrolimus for eczemaRandomised trials in context: practical problems and social aspects of evidence-based medicine and policyThe objective severity assessment of atopic dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitisA randomised controlled trial of ion-exchange water softeners for the treatment of eczema in childrenEfficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.Serum mucosa-associated epithelial chemokine in atopic dermatitis: a specific marker for severityEfficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials.Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis.Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.Chinese herbal medicine granules (PTQX) for children with moderate to severe atopic eczema: study protocol for a randomised controlled trial.Consensus guidelines in diagnosis and treatment of atopic dermatitis.Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review.The effects of psychological intervention on atopic dermatitis. A systematic review and meta-analysis.Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods.Investigating quality of life and health-related quality of life in infertility: a systematic review.Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials.Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting.A meta-analysis of the effectiveness of psychological interventions for adults with skin conditions.Future horizons in vitiligo research: focusing on the recommendations of the Cochrane systematic review 'Interventions for vitiligo' 2010.Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer.Objective evaluation for severity of atopic dermatitis by morphologic study of skin surface contours.Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process.Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review.Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.Barrier-restoring therapies in atopic dermatitis: current approaches and future perspectivesDevelopment and validation of a photonumeric grading scale for assessing lip volume and thickness.Atopic dermatitis is more severe in children over the age of two who have an increased body mass index.The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability.A simple method to assess severity of polymorphic light eruption.Determining the severity of atopic dermatitis in children presenting in general practice: an easy and fast method.Clinical trials in dermatology.Effect of standard medication on quality of life of patients with atopic dermatitis.Validation of CADESI-03, a severity scale for clinical trials enrolling dogs with atopic dermatitis.Eczema (atopic).Clinical Signs, Staphylococcus and Atopic Eczema-Related Seromarkers.Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis.Different effect of oral cyclosporine therapy and oral antihistamine therapy on serum high-sensitivity C-reactive protein level and thymus and activation-regulated chemokine level in atopic dermatitis in older children and adulthood.SCORAD 75: a new metric for assessing treatment outcomes in atopic dermatitis.
P2860
Q24199012-EB9CBA95-C3A7-4CCA-85B1-CF57EC77E0F6Q24243250-33C05E0F-98A6-46C4-AD5B-0B1305A8F527Q26784106-4A909AB5-074D-4EDC-BB13-E67FBD120182Q28273743-845A7CD1-5F7D-47D3-AB12-DD154BBDEF97Q28742745-316E37EC-BE35-4AEC-B70E-4FC5702F4EBCQ31149849-2982883E-9FF8-4EE1-9406-BA9DA1F2FB77Q33607633-69B5D31E-C94E-4699-A4DD-3E93A1728E76Q33684930-45D9719E-CB02-4C43-8F57-A17AF1843954Q33785053-ED4908C1-B36D-4420-A7F4-575AE54776F1Q34497913-B98C7CA5-AD57-4B14-938F-1C77B796707CQ35831371-CA2BF57D-F5B3-4D10-88C3-5DC162196475Q35831654-90E43C0C-50A9-4AC9-B3AC-CF43C51DAFBAQ36056978-D87D9375-EF03-43A9-BEEB-941D8579F3D2Q36798178-BB492E5B-EC5F-4671-BB5C-33ED5F90B0B8Q37576874-8E10F9A7-28DB-4484-9FB3-93D9B5CC8F38Q37742616-43498A9A-DFF9-4B79-BE41-1C2CE0B22EC6Q38010463-E951C92A-A36B-4C5A-B937-A6CF5B666359Q38030564-08872E09-8A9A-4A5E-9035-98AE3A45EEBEQ38038276-4BFB82BC-3FC8-49C9-8B4E-B2F6F053F26EQ38149877-2FF4ACAF-B5C0-46EA-BD72-21B0967F61AFQ38375544-F3AB22E6-8D4B-428F-A06D-E0172D7B9B67Q38512697-335AC5E5-B8E4-4522-87DF-AB4A661C5190Q38732070-CEE342FC-7BE5-45CF-8FDE-6B1598A32D6FQ38787972-592372A8-DEE7-46E0-AF4E-65B0786186B9Q38794071-877CEB84-8240-489D-9AF2-C59B54A326B8Q39556853-F9A4554C-FED6-4218-8CF4-994B6557AF92Q39949603-BE830004-625C-441A-B22F-ABB5EBCD4904Q40255743-ADAAA3AE-8EDD-4A7D-A4CC-19E3E7F2F66DQ40443395-5B4FA6A9-B2D6-4D8A-BA06-7250676371F8Q40481838-FAEA24EA-89C9-4D73-AC11-3B559C312503Q40852027-12AA6AFC-2E43-4B4A-9782-FDBB081518ECQ41378761-7EEBCAB2-FA79-4C76-8B4A-05E727CA181DQ42608053-C08E5C6F-7C12-43F7-8554-886E4E26EE2BQ44869807-BBDF99A0-1677-45A8-89BB-CBDEBAD11F4BQ46721613-A2DD090D-1C43-4ADC-9A9F-B9D0F4520D4AQ47574303-B2BE0901-6A29-4AE2-A5AF-6198AAA4337AQ48172634-F698863C-A2D2-4F65-98CA-A65E11D0FEA6Q48491865-47BE2B2F-FE20-4A0F-A966-67F2382574FCQ51107316-A3462998-2557-4C6D-840A-11F7418B9158Q51391058-1C5E5792-3E9D-4DA2-9789-D23A650A645C
P2860
Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring?
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Measuring atopic dermatitis se ...... what exactly are we measuring?
@ast
Measuring atopic dermatitis se ...... what exactly are we measuring?
@en
type
label
Measuring atopic dermatitis se ...... what exactly are we measuring?
@ast
Measuring atopic dermatitis se ...... what exactly are we measuring?
@en
prefLabel
Measuring atopic dermatitis se ...... what exactly are we measuring?
@ast
Measuring atopic dermatitis se ...... what exactly are we measuring?
@en
P2093
P1476
Measuring atopic dermatitis se ...... what exactly are we measuring?
@en
P2093
Carolyn Charman
Colette Chambers
Hywel Williams
P304
P356
10.1046/J.1523-1747.2003.12251.X
P407
P577
2003-06-01T00:00:00Z
P5875
P6179
1034471928